-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

626.O1.6 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Results from CAR T-Cell Trials

Program: Oral and Poster Abstracts
Type: Oral
Saturday, December 7, 2019: 2:00 PM-3:30 PM
Hall E2, Level 2 (Orange County Convention Center)
Moderators:
Leslie L. Popplewell, MD, FRCPA, City of Hope Medical Center and Collin Chin, MBBS, Peter MacCallum Cancer Centre
Disclosures:
No relevant conflicts of interest to declare.
2:00 PM

Jeremy S. Abramson, MD, MMSc1, Maria Lia Palomba, MD2, Leo I. Gordon, MD3, Matthew A. Lunning, DO, FACP4, Michael L. Wang, MD5, Jon E. Arnason, MD6, Amitkumar Mehta, MD7, Enkhtsetseg Purev, MD, PhD8, David G. Maloney, MD PhD9, Charalambos Andreadis, MD, MSCE10*, Alison R. Sehgal, MD11, Scott R. Solomon, MD12, Nilanjan Ghosh, MD, PhD13, Tina Albertson, MD14, Jacob Garcia, MD14, Ana Kostic14*, Daniel Li, PhD14*, Yeonhee Kim14* and Tanya Siddiqi, MD15*

1Massachusetts General Hospital Cancer Center, Boston, MA
2Memorial Sloan Kettering Cancer Center, New York, NY
3Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
4University of Nebraska Medical Center, Omaha, NE
5University of Texas MD Anderson Cancer Center, Houston, TX
6Beth Israel Deaconess Medical Center, Boston, MA
7Department of Hematology/Oncology Medicine, University of Albama At Birmingham, Birmingham, AL
8University of Colorado School of Medicine, Aurora, CO
9Fred Hutchinson Cancer Research Center, Seattle, WA
10University of California, San Francisco, San Francisco, CA
11University of Pittsburgh Medical Center, Pittsburgh, PA
12Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA
13Levine Cancer Institute, Atrium Health, Charlotte, NC
14Juno Therapeutics, Inc., a Celgene Company, Seattle, WA
15City of Hope National Medical Center, Duarte, CA

2:15 PM

Veronika Bachanova, MD, PhD1, Constantine S. Tam, MBBS, MD2*, Peter Borchmann3, Ulrich Jaeger, MD4, Joseph P. McGuirk, DO5, Harald Holte, MD, PhD6, Edmund K. Waller, PhD, MD7, Samantha Jaglowski, MD, MPH8, Michael R. Bishop, MD9, Charalambos Andreadis, MD, MSCE10*, Stephen Ronan Foley, MD, FRCPC11, Jason R. Westin, MD12, Isabelle Fleury, MD13*, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA)14*, Stephan Mielke, MD15, Takanori Teshima, MD16, Gilles A. Salles, MD, PhD17, Stephen J Schuster, MD18, Richard T. Maziarz, MD19, Koen Van Besien, MD, PhD20, Koji Izutsu, MD, PhD21*, Marie Jose Kersten, MD, PhD22, John M. Magenau, MD23*, Nina D. Wagner-Johnston, MD24,25, Koji Kato, MD, PhD26, Paolo Corradini, MD27, Jufen Chu, PhD28*, Irina Gershgorin, PhD28*, Therese Choquette, PhD28*, Lida Bubuteishvili Pacaud, MD28* and Margit Jeschke, PhD29*

1Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
2Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
3Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Koln, Germany
4Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Vienna General Hospital - Medical University of Vienna, Vienna, AA, Austria
5Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
6Norwegian Cancer Genomics Consortium, Oslo, Norway
7Winship Cancer Institute, Emory University, Atlanta, GA
8The Ohio State University, Columbus, OH
9Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
10Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
11Hamilton Health Sciences, Hamilton, ON, CAN
12Department of Lymphoma and Myeloma, MD Anderson, Houston, TX
13Maisonneuve-Rosemont Hospital and University of Montreal, Montreal, Canada
14Department of Haematology, Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
15University of Würzburg, Center of Allogeneic Stem Cell Transplantation, Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany
16Department of Hematology, Hokkaido University Hospital, Sapporo Hokkaido, Japan
17Lyon-Sud University Hospital Complex, Pierre-Bénite, France
18Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
19Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR
20Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY
21Department of Hematology, Toranomon Hospital, National Cancer Center Hospital, Tokyo, Japan
22Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
23Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI
24Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD
25Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
26Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan
27Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy
28Novartis Pharmaceuticals Corporation, East Hanover, NJ
29Novartis Pharma AG, Basel, Switzerland

2:30 PM

Max Topp, MD1*, Tom Van Meerten, MD, PhD2,3*, Roch Houot, MD, PhD4*, Monique C. Minnema3,5, Noel Milpied, MD6*, Pieternella J. Lugtenburg, MD, PhD3,7, Catherine Thieblemont, MD PhD8, Martin Wermke, MD9*, Kevin Song, MD10, Irit Avivi, MD11*, John Kuruvilla, MD12, Ulrich Dührsen, Prof, MD, PhD13*, Rachel Chu, PhD14*, Lianqing Zheng, PhD14*, Vicki Plaks, PhD14*, Anne Kerber, MD14* and Marie Jose' Kersten, MD, PhD3,15

1Medizinische Klinik und Poliklinik II, Universitätsklinikum, Würzburg, Würzburg, Germany
2University Medical Center Groningen, Groningen, DC, Netherlands
3on behalf of HOVON/LLPC (Lunenburg Lymphoma Phase I/II Consortium), Rotterdam, Netherlands
4University Hospital of Rennes, Rennes, FRA
5Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
6Hématologie Clinique et Thérapie cellulaire, CHU Bordeaux; Service d’hematologie et therapie Cellulaire, F-33000, Bordeaux, France
7Erasmus MC, Lunenburg Lymphoma Phase I/II Consortium – HOVON /LLPC, Rotterdam, Netherlands
8Hopital Saint Louis, paris, France
9NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany
10The University of British Columbia, Vancouver, BC, Canada
11Department of Hematology, Sourasky Medical Center, Tel Aviv, Israel
12Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada
13University Hospital Essen, Essen, Germany
14Kite, a Gilead Company, Santa Monica, CA
15Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

2:45 PM

Javier Munoz, MD1*, Samantha Jaglowski, MD, MPH2, Matthew S. McKinney, MD3, Iris Isufi, MD4, Patrick J. Stiff, MD5, Jessica Sachs, MD6*, Ann Ranger, PhD6*, Patricia Harris, MPH6*, Francis Payumo, BSc, MSc6* and Luke P. Akard, MD7

1Banner MD Anderson Cancer Center, Gilbert, AZ
2The Ohio State University, Columbus, OH
3Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
4Hematology, Yale University School of Medicine, New Haven, CT
5Loyola University Medical Center, Maywood, IL
6Unum Therapeutics Inc., Cambridge, MA
7Indiana Bone and Marrow Transplantation, Franciscan Health, Indianapolis, IN

3:00 PM

Michael D. Jain, MD, PhD1, Miriam T. Jacobs, MD2, Loretta J. Nastoupil, MD3, Jay Y. Spiegel, MD, FRCPC4, Gao Feng5*, Yi Lin, MD, PhD6, Matthew A. Lunning, DO, FACP7, Saurabh Dahiya, MD8, Lazaros J Lekakis, MD9*, Patrick M Reagan, MD10, Olalekan O. Oluwole, MBBS, MPH11, Joseph P. McGuirk, DO12, Abhinav Deol, MD13, Andre Goy, MD14, Brian T. Hill, MD15,16, Javier Munoz, MD17*, Julio Chavez18*, Aaron P. Rapoport19, Julie M Vose, MD MBA20, David B Miklos, MD, PhD21, Sattva S Neelapu, MD3, N. Nora Bennani, MD6, Charalambos Andreadis, MD, MSCE22*, Alison R. Sehgal, MD23, Armin Ghobadi, MD24 and Frederick L. Locke, MD1

1Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
2Department of Oncology, Washington University in St. Louis, St Louis, MO
3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA
5Washington University in St. Louis, St. Louis, MO
6Division of Hematology, Mayo Clinic, Rochester, MN
7University of Nebraska Medical Center, Omaha, NE
8University of Maryland School of Medicine, Ellicott City, MD
9University of Miami, Sylvester Comprehensive Care Center, Miami, FL
10Wilmot Cancer Institute Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY
11Division of Hematology-Oncology, Vanderbilt Univeristy, Nashville, TN
12Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
13Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/Wayne State University, Detroit, MI
14Department of Hematology & Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
15Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
16Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
17Banner MD Anderson Cancer Center, Gilbert, AZ
18Dept. of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
19University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD
20Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE
21Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA
22Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
23UPMC Hillman Cancer Center, Pittsburgh, PA
24Washington University School of Medicine, Saint Louis, MO

3:15 PM

Kirit M. Ardeshna, MBBChir1, Maria A V Marzolini2*, Jane Norman, MD3*, Muhammad Al-Hajj, PhD, BSc4, Simon Thomas, PhD4*, Jim Faulkner4*, Ekaterini Kotsopoulou4*, Martin Pule, MD4*, Vijay G R Peddareddigari4*, Nushmia Z Khokhar4*, Maud Jonnaert, PhD5*, Robert Chen, MD5 and Wendy Osborne, MD6*

1Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom
2UCL Cancer Institute, London, United Kingdom
3Manchester University NHS, Manchester, United Kingdom
4Autolus Ltd, London, United Kingdom
5Autolus Therapeutics, London, United Kingdom
6Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

*signifies non-member of ASH